دوره 11، شماره 2 - ( 3-1402 )
جلد 11 شماره 2 صفحات 92-87 |
برگشت به فهرست نسخه ها
Ethics code: Ethics approval code: IR.TUMS.VCR.REC.1399.103
Clinical trials code: Ethics approval code: 99-1-101-47345
، macasty1234@gmail.com
چکیده: (1065 مشاهده)
Background and Purpose: Numerous comorbidities are involved in the severity of the new coronavirus disease 2019 (COVID-19). Hypothyroidism’s impact on COVID-19 is yet to be adequately understood. Thyroid disorders are thought to play a role in the development and progress of COVID-19. This study aimed to determine the frequency of hypothyroidism among COVID-19 patients in hospitalized patients.
Materials and Methods: This retrospective cross-sectional study was conducted at a tertiary hospital in Tehran City, Iran. Demographic information and other specified data related to our research, mainly comorbidities, were collected using a structured questionnaire from electronic patient health records. A total of 493 medical records of COVID-19 patients were used for this study according to the inclusion criteria. Subsequently, the data were analyzed with SPSS, version 25, using descriptive and analytic statistics.
Results: The prevalence of hypothyroidism was 13.2% (n=65) in hospitalized COVID-19 patients. This was higher (13.4% vs 2.3%) compared with the prevalence of hypothyroidism in the general Iranian population. Overall, in patients with hypothyroidism, about 21 patients (32.3%) expired, of whom 14 patients (66.7%) were female, and 7 (33.3%) were male. In these patients, no statistically significant difference was observed between the expired and discharged groups (Adjusted Odds Ratio: 1.04; 95% CI 0.59-1.83; P=0.87). As a result, hypothyroidism was not linked to an increased risk of death.
Conclusion: Hypothyroidism in hospitalized COVID-19 patients appears to be low. However, it seems more prevalent in the female gender but without significant adverse effects on the risk of mortality from this disease.
Materials and Methods: This retrospective cross-sectional study was conducted at a tertiary hospital in Tehran City, Iran. Demographic information and other specified data related to our research, mainly comorbidities, were collected using a structured questionnaire from electronic patient health records. A total of 493 medical records of COVID-19 patients were used for this study according to the inclusion criteria. Subsequently, the data were analyzed with SPSS, version 25, using descriptive and analytic statistics.
Results: The prevalence of hypothyroidism was 13.2% (n=65) in hospitalized COVID-19 patients. This was higher (13.4% vs 2.3%) compared with the prevalence of hypothyroidism in the general Iranian population. Overall, in patients with hypothyroidism, about 21 patients (32.3%) expired, of whom 14 patients (66.7%) were female, and 7 (33.3%) were male. In these patients, no statistically significant difference was observed between the expired and discharged groups (Adjusted Odds Ratio: 1.04; 95% CI 0.59-1.83; P=0.87). As a result, hypothyroidism was not linked to an increased risk of death.
Conclusion: Hypothyroidism in hospitalized COVID-19 patients appears to be low. However, it seems more prevalent in the female gender but without significant adverse effects on the risk of mortality from this disease.
نوع مطالعه: پژوهشي |
موضوع مقاله:
اپيدميولوژي
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |